Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Reinaldo P. Furlanetto is active.

Publication


Featured researches published by Reinaldo P. Furlanetto.


Clinical Endocrinology | 2004

Comparison of practical methods for urinary glycosaminoglycans and serum hyaluronan with clinical activity scores in patients with Graves' ophthalmopathy

João Roberto Maciel Martins; Reinaldo P. Furlanetto; Lhoyane M. Oliveira; Aline Mendes; Carlo C. Passerotti; Maria Izabel Chiamolera; Antônio José da Rocha; Paulo Gois Manso; Helena B. Nader; Carl P. Dietrich; Rui M. B. Maciel

objective  Immunosuppressive treatment of Graves’ opthalmopathy (GO) should be restricted to patients with active eye disease, but assessing disease activity is difficult. Several methods to evaluate GO activity have been introduced, but none of them is satisfactory. Glycosaminoglycans (GAGs) are complex polysaccharides that participate on the pathogenesis of GO and attempts to correlate its local increase to urinary GAGs (uGAGs) or serum hyaluronan (sHA) have been made, but the available techniques are labourious, time‐consuming and difficult for routine use. The aim of the present study is to develop practical and simple methods for uGAGs and sHA and compare them to the activity and severity of thyroid‐associated ophthalmopathy.


Arquivos Brasileiros De Endocrinologia E Metabologia | 2007

Diagnóstico de metástases de carcinoma papilífero de tiróide através da dosagem de tiroglobulina no líquido obtido da lavagem da agulha utilizada na punção aspirativa

Rosa Paula M. Biscolla; Elza S. Ikejiri; Maria Conceição Mamone; Cláudia C. D. Nakabashi; Victor P. Andrade; Teresa S. Kasamatsu; Felipe Crispim; Maria Izabel Chiamolera; Danielle M. Andreoni; Cléber P. Camacho; Flávio C. Hojaij; José Gilberto H. Vieira; Reinaldo P. Furlanetto; Rui M. B. Maciel

The widespread use of neck ultrasonography (US) during the follow-up of patients with papillary thyroid carcinoma (PTC) has led to the discovery of small cervical lymph nodes (LN). Although US has a high sensitivity for diagnosing LN, fine needle aspiration biopsy (FNA) and measurement of thyroglobulin in fine needle aspirates (FNA-Tg) have proven to be invaluable tools. The aim of this study is to determine the sensitivity of the combined use of neck US, FNA biopsy and FNA-Tg for diagnosis of cervical lymph nodes. We have studied 32 patients with 44 LN detected by US, 19 classified as inflammatory and 25 as suspicious. 15 of those 25 suspicious LN had high FNA-Tg (13 of the 15 had positive cytology and 2 indeterminate). All of these 15 LN (11 patients) were proven to be PTC metastasis by histopathology. All 19 inflammatory LN and those 10/25 suspicious LN, had cytology negative for malignancy and undetectable FNA-Tg. We conclude that fine needle aspiration biopsy and FNA-Tg combined with neck US are essential for detecting positive cervical lymph nodes due to its high sensitivity and specificity and it should be considered the standard for investigating locally recurrent disease in patients with PTC.


Thyroid | 2012

Lithium as an adjuvant in the postoperative ablation of remnant tissue in low-risk thyroid carcinoma.

Claudia A. Yamazaki; Rosália P. Padovani; Rosa Paula M. Biscolla; Elza Setsuko Ikejiri; Renata Rosa Marchetti; Mario Luiz Vieira Castiglioni; Luiza K. Matsumura; Rui M. B. Maciel; Reinaldo P. Furlanetto

BACKGROUND Thyroid remnant ablation (RA) with 30 mCi of radioactive iodine (131I) in patients thyroidectomized for treatment of low-risk differentiated thyroid carcinoma (DTC) has a success rate of 64% to 84%. Lithium increases the residence time of 131I in the thyroid tissue. The aim of this study was to determine if lithium treatment added to 30 mCi 131I would enhance the success rate of this treatment compared with 30 mCi 131I alone in patients who were thyroidectomized for treatment of low-risk DTC. METHODS This was a randomized study with endpoint at one year. Sixty one consecutive patients were enrolled and randomized into two groups: group A (n=32) treated with 30 mCi 131I; group B (n=29) treated with 30 mCi 131I plus an oral dose of lithium 900 mg/day, for 7 days. All patients were evaluated by whole body scan (WBS) with 123I and had serum TSH, thyroglobulin (Tg), and anti-Tg antibodies (TgAb) determined when they were hypothyroid on no thyroid hormone. Patients were reevaluated after one year with serum TSH, Tg, and TgAb determinations and WBS with 123I. The criteria for defining a successful outcome was a negative WBS and a serum Tg of <1. RESULTS Group A was composed of 28 women and four men (ages 25-71 years) with 2 having follicular thyroid carcinoma (FTC), 22 having papillary thyroid carcinoma (PTC) of 1-4.5 cm, and 8 having micro PTCs (mPTC) of 0.3-0.8 cm. Group B was composed of 26 women and 3 men (ages 20-63 years) with 3 having FTC, 15 having PTC of 1.2-3.5 cm, and 11 having mPTC of 0.2-0.8 cm. All patients had a history of a WBS after their post-therapeutic 131I dose that showed uptake in the cervical region. After one year, 22 patients from group A had a negative WBS (68.75%) and in group B, 27 patients had a negative WBS (93.1%). The successful rates for the follow-up WBS were significantly different (p=0.017). There were 19 patients in group A in whom the initial Tg was positive. Of these, 14 had a negative follow-up Tg (73.7%). Group B had 9 patients with a positive initial Tg and all of them had a negative follow-up Tg (100%). CONCLUSION The addition of lithium to treatment with 30 mCi 131I in thyroidectomized patients with low-risk DTC improved the efficacy of thyroid RA and therefore might be a better alternative than using higher doses of 131I for remnant ablation in these patients.


Arquivos Brasileiros De Endocrinologia E Metabologia | 2003

Injeção percutânea de etanol no tratamento de nódulos tiroidianos sólidos, císticos e autônomos

Elizabeth X. Bianchini; Elza S. Ikejiri; Maria Conceição Mamone; Elias R. Paiva; Rui M. B. Maciel; Reinaldo P. Furlanetto

Percutaneous ethanol injection (PEI) guided by ultrasound has been used for the treatment of cystic, solid and autonomous thyroid nodules. We present our experience in the treatment of 50 patients with thyroid nodules: 26 solid, 17 cystic and 7 autonomous (AN). Patients were evaluated 1 week, 1, 3, and 6 months and 1 year after PEI. After one year, solid nodules showed a mean 74% volume reduction, and cysts a volume reduction of 92%, with no recurrences. After one year, 5 patients with AN reached clinical and laboratory euthyroidism; the other 2 also became euthyroid, but with subnormal TSH. Recurrence of thyrotoxicosis was not observed and mean nodular reduction was 66%. The procedure was well tolerated by all patients. The results confirm that PEI is a good therapeutic alternative for reduction of solid and cystic thyroid nodules and for the treatment of autonomous nodules.


Arquivos Brasileiros De Endocrinologia E Metabologia | 2011

Avaliação de fatores clínicos, laboratoriais e ultrassonográficos preditores de malignidade em nódulos tiroidianos

Ana Luiza Silva Rio; Rosa Paula M. Biscolla; Danielle M. Andreoni; Cléber P. Camacho; Cláudia C. D. Nakabashi; Maria Conceição Mamone; Elza S. Ikejiri; Luiza K. Matsumura; Jairo T. Hidal; Rui M. B. Maciel; Reinaldo P. Furlanetto

OBJECTIVE: To evaluate the risk of malignancy in thyroid nodules through clinical, laboratory, ultrasonographic and cytological aspects. PATIENTS AND METHODS: 741 nodules of 407 patients. RESULTS: The cytology was benign (60,5%), indeterminate (23,3%), malignant (8,3%) or nondiagnostic (7,6%). The prevalence of cancer in indeterminate citology was 18,5% (16% in follicular lesions, 44% in suspicious). The diagnosis of malignancy was 17,2% (n = 70). The frequency of cancer in women (15,2%) was lower than in men (27,9%). There was an inverse relation between age and cancer risk. There was no statistical significance in the prevalence of cancer according to number, size of nodules or TSH levels. Hypoechogenicity and microcalcifications on ultrasound were risk factors. CONCLUSION: The risk of malignancy was higher in men, hypoechoic nodules, with microcalcifications and was inversely related to age. The TSH level was not an independent factor predictive of malignancy.


Arquivos Brasileiros De Endocrinologia E Metabologia | 2004

Incidência de malignidade na doença nodular da tiróide com baixa suspeita clínica: estudo observacional prospectivo por dois anos numa coorte de 50 pacientes

Claudia A. Yamazaki; M. Conceição C. Mamone; Elza S. Ikejiri; Jairo T. Hidal; Luiza K. Matsumura; Flávio C. Hojaij; Onivaldo Cervantes; Márcio Abrahão; Reinaldo P. Furlanetto; Rui M. B. Maciel

INTRODUCTION: To study the frequency of malignant lesions in patients with clinically benign thyroid nodules and the value of the repetition of fine needle aspiration biopsy (FNAB). METHODS: Observational and prospective 2-year study in a cohort of 50 patients with clinically benign thyroid nodules. Patients were initially submitted to clinical examination, ultrasound (US) and FNAB1 patients, followed by a second FNAB and US. RESULTS: Palpation is not a good test for diagnosis and follow-up of thyroid nodules. On the other hand, the initial consideration that these patients should harbor benign lesions is a very useful parameter, since 47/50 patients (94%) did not present malignant lesions during the follow-up. FNAB1 and FNAB2 were concordant in 33/39 patients when FNAB1 was negative (85%); 11 patients were operated, 8 by suspicious FNAB and 3 due to nodule growth. We observed 2 patients with non-invasive papillary microcarcinoma and 1 patient with papillary carcinoma outside of the main nodules. CONCLUSION: there was concordance between initial clinical benign diagnosis, FNAB and the follow-up. In one case there was a papillary carcinoma. In addition, ultrasonography should be considered for all patients with suspected thyroid nodules. Finally, we demonstrated that a second cytology usually confirms the result of the first cytology in benign thyroid nodules.


Endocrine Practice | 1999

THYROID SUPPRESSION TEST WITH A SINGLE ORAL DOSE OF LEVOTHYROXINE IN THE DIAGNOSIS OF FUNCTIONAL THYROID AUTONOMY

Andréa M. Britto-Fioretti; Reinaldo P. Furlanetto; Elias R. Paiva; Ilda S. Kunii; Magnus R. Dias da Silva; Rui M. B. Maciel

OBJECTIVE To propose a modified form of thyroid suppression test with use of a single oral dose of levothyroxine (35 mg/kg). METHODS After a baseline scintigram, 23 patients with nodular goiter suspected of autonomous function (warm or hot nodules, subnormal or undetectable thyrotropin levels, or both findings) and 14 normal subjects underwent a repeated scintigram 4 days after administration of levothyroxine. We evaluated triiodothyronine (T(3)), free thyroxine, and thyrotropin before and on the first, second, third, fourth, and seventh days after administration of the individualized dose of levothyroxine. RESULTS The 99th percentile of postsuppression uptake in normal subjects was determined, and an uptake >12.4%, a 131 I concentration restricted to the nodule, or both factors were adopted as the criteria for diagnosis of an autonomously functioning thyroid nodule. Twelve patients were considered to have autonomously functioning nodules, and 11 patients were considered to have nonautonomous nodules. Baseline thyrotropin levels in patients with autonomous nodules did not differ significantly from those in patients with nonautonomous nodules. No signs or symptoms of toxicity were detected during the test, but all study subjects had increased free thyroxine values, and seven had high levels of T(3). CONCLUSION The thyroid suppression test with 35 mg/kg of levothyroxine is an effective method for the diagnosis of an autonomously functioning thyroid nodule, is nontoxic, and avoids the inaccurate use of the medication occasionally observed with T(3). Even sensitive methods of thyrotropin determination cannot replace this test in the evaluation of autonomous thyroid function.


Thyroid | 1998

Prospective and controlled study of ophthalmopathy after radioiodine therapy for Graves' hyperthyroidism.

Paulo Gois Manso; Reinaldo P. Furlanetto; Angela Maria Borri Wolosker; Elias R. Paiva; Mariza Toledo de Abreu; Rui M. B. Maciel


European Journal of Ophthalmology | 2004

Pentoxifylline (PTX): An alternative treatment in Graves' ophthalmopathy (inactive phase): Assessment by a disease specific quality of life questionnaire and by exophthalmometry in a prospective randomized trial

F. E. Finamor; J. R. M. Martins; D. Nakanami; E. R. Paiva; Paulo Gois Manso; Reinaldo P. Furlanetto


Arquivos Brasileiros De Oftalmologia | 2006

Colchicine in the treatment of the inflammatory phase of Graves' ophthalmopathy: a prospective and randomized trial with prednisone

Francisco Stamato; Rui Monterio de Barros Maciel; Paulo Gois Manso; Angela Maria Borri Wolosker; Elias R. Paiva; Antonio Carlos Lopes; Reinaldo P. Furlanetto

Collaboration


Dive into the Reinaldo P. Furlanetto's collaboration.

Top Co-Authors

Avatar

Rui M. B. Maciel

Federal University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

Elza S. Ikejiri

Federal University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

Elias R. Paiva

Federal University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

Luiza K. Matsumura

Federal University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

Maria Conceição Mamone

Federal University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

Paulo Gois Manso

Federal University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

Jairo T. Hidal

Federal University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

Rosa Paula M. Biscolla

Federal University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

Cláudia C. D. Nakabashi

Federal University of São Paulo

View shared research outputs
Top Co-Authors

Avatar

Cléber P. Camacho

Federal University of São Paulo

View shared research outputs
Researchain Logo
Decentralizing Knowledge